WO2008149521A1 - 癌治療剤及び癌の治療方法 - Google Patents

癌治療剤及び癌の治療方法 Download PDF

Info

Publication number
WO2008149521A1
WO2008149521A1 PCT/JP2008/001346 JP2008001346W WO2008149521A1 WO 2008149521 A1 WO2008149521 A1 WO 2008149521A1 JP 2008001346 W JP2008001346 W JP 2008001346W WO 2008149521 A1 WO2008149521 A1 WO 2008149521A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
therapeutic agent
treatment
growth factor
factor receptor
Prior art date
Application number
PCT/JP2008/001346
Other languages
English (en)
French (fr)
Inventor
Kohzoh Imai
Shigeru Sasaki
Tsutomu Seito
Original Assignee
Immuno-Biological Labolatories Co., Ltd
Sapporo Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno-Biological Labolatories Co., Ltd, Sapporo Medical University filed Critical Immuno-Biological Labolatories Co., Ltd
Priority to CA2689242A priority Critical patent/CA2689242C/en
Priority to US12/601,811 priority patent/US8481497B2/en
Priority to EP08763946.4A priority patent/EP2165715B1/en
Priority to JP2009517707A priority patent/JP5563818B2/ja
Publication of WO2008149521A1 publication Critical patent/WO2008149521A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/53—Liver

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

【課題】ＦＧＦＲ１を標的とした癌の抗体療法において、特異性が高く細胞殺傷作用の強い効果的な抗体を用いなくとも、効果的に癌の抗体療法を行うことのできる技術を提供すること。 【解決手段】線維芽細胞増殖因子受容体１発現亢進剤と、抗線維芽細胞増殖因子受容体１抗体とを含有することを特徴とする癌治療剤及びこれを用いた癌の治療方法。  
PCT/JP2008/001346 2007-05-29 2008-05-29 癌治療剤及び癌の治療方法 WO2008149521A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA2689242A CA2689242C (en) 2007-05-29 2008-05-29 Agent and method for treatment of cancer
US12/601,811 US8481497B2 (en) 2007-05-29 2008-05-29 Therapeutic agent for cancer, and method for treatment of cancer
EP08763946.4A EP2165715B1 (en) 2007-05-29 2008-05-29 Therapeutic agent for cancer, and method for treatment of cancer
JP2009517707A JP5563818B2 (ja) 2007-05-29 2008-05-29 癌治療剤及び癌の治療方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-142308 2007-05-29
JP2007142308 2007-05-29

Publications (1)

Publication Number Publication Date
WO2008149521A1 true WO2008149521A1 (ja) 2008-12-11

Family

ID=40093353

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/001346 WO2008149521A1 (ja) 2007-05-29 2008-05-29 癌治療剤及び癌の治療方法

Country Status (5)

Country Link
US (1) US8481497B2 (ja)
EP (1) EP2165715B1 (ja)
JP (1) JP5563818B2 (ja)
CA (1) CA2689242C (ja)
WO (1) WO2008149521A1 (ja)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010087319A1 (ja) * 2009-01-27 2010-08-05 アステラス製薬株式会社 前立腺癌治療剤として有効な物質のスクリーニング方法
JP2012025694A (ja) * 2010-07-23 2012-02-09 Asahi Kasei Kuraray Medical Co Ltd 癌治療剤
US8324160B2 (en) 2009-06-17 2012-12-04 Amgen Inc. Chimeric polypeptides and uses thereof
US8372952B2 (en) 2009-12-02 2013-02-12 Amgen Inc. Binding proteins that bind to human FGFR1C, human β-klotho and both human FGFR1C and human β-klotho
WO2013129549A1 (ja) * 2012-02-29 2013-09-06 東レ株式会社 体腔液貯留抑制剤
US8795985B2 (en) 2009-05-05 2014-08-05 Amgen Inc. FGF 21 polypeptides comprising two or more mutations and uses thereof
WO2014138364A2 (en) 2013-03-06 2014-09-12 Genentech, Inc. Methods of treating and preventing cancer drug resistance
JP2014523866A (ja) * 2011-05-16 2014-09-18 ジェネンテック， インコーポレイテッド Ｆｇｆｒ１アゴニスト及び使用方法
JP2015530976A (ja) * 2012-07-24 2015-10-29 ザ トラスティーズ オブ コロンビア ユニバーシティ イ 融合タンパク質およびその方法
WO2015191986A1 (en) 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance
US9279013B2 (en) 2008-10-10 2016-03-08 Amgen Inc. FGF-21 mutants comprising polyethylene glycol and uses thereof
US9284378B2 (en) 2009-12-07 2016-03-15 Shaw-Fen Sylvia Hu Human antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereof
US9493530B2 (en) 2009-05-05 2016-11-15 Amgen Inc. FGF21 mutants comprising a mutation at position 98, 171 and/or 180
US11072640B2 (en) 2008-06-04 2021-07-27 Amgen Inc. Methods of treating non-alcoholic steatohepatitis using FGF21 mutants
US11920138B2 (en) 2012-07-24 2024-03-05 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG185832A1 (en) 2011-05-10 2012-12-28 Agency Science Tech & Res Fgfr1 antibodies and treatment of cancer
WO2015003021A2 (en) * 2013-07-01 2015-01-08 The Trustees Of Princeton University Dietary supplements and composition for treating cancer
RU2638457C2 (ru) * 2015-09-28 2017-12-13 Общество С Ограниченной Ответственностью "Онкомакс" Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066772A2 (en) * 2000-03-08 2001-09-13 Massachusetts Institute Of Technology Heparinase iii and uses thereof
AU2002329540A1 (en) * 2001-06-20 2003-01-02 Morphosys Ag Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
AU2004312376A1 (en) 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
NZ565511A (en) * 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
"Interferon-gamma down-regulates expression of tumor necrosis factor-alpha converting enzyme/a disintegrin and metalloproteinase 17 in activated hepatic stellate cells of rats", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 17, 2006, pages 605 - 616
BIER H. ET AL.: "Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell -mediated cytotoxicity against squamous cell carcinoma lines of the head and neck", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 46, no. 3, May 1998 (1998-05-01), pages 167 - 173, XP002252113, ISSN: 0340-7004 *
DAMDINSUREN B. ET AL.: "Interferon-beta is more potent than interferon-alpha in inhibition of human hepatocellular carcinoma cell growth when used alone and in combination with anticancer drugs", ANNALS OF SURGICAL ONCOLOGY, vol. 10, no. 10, 2003, pages 1184 - 1190, XP019369213, ISSN: 1068-9265 *
DAMDINSUREN B. ET AL.: "Stronger growth- inhibitory effect of interferon (IFN)-beta compared to IFN-alpha is mediated by IFN signaling pathway in hepatocellular carcinoma cells", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 30, no. 1, January 2007 (2007-01-01), pages 201 - 208, XP007913629, ISSN: 1019-6439 *
FUJIOKA N. ET AL.: "Role of p53 in the inhibitory effects of interferon-alpha subtypes on proliferation of hepatocellular carcinoma cells", BIOMEDICAL RESEARCH, vol. 27, no. 5, October 2006 (2006-10-01), pages 219 - 226, XP007913627, ISSN: 0388-6107 *
GENNARI R. ET AL.: "Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2", CLINICAL CANCER RESEARCH, vol. 10, no. 17, 2004, pages 5650 - 5655, XP008126828, ISSN: 1078-0432 *
HISAKA T. ET AL.: "Interferon-alphaCon1 suppresses proliferation of liver cancer cell lines in vitro and in vivo", JOURNAL OF HEPATOLOGY, vol. 41, no. 5, November 2004 (2004-11-01), pages 782 - 789, XP004617757, ISSN: 0168-8278 *
HUANG X. ET AL.: "Ectopic activity of fibroblast growth factor receptor 1 in hepatocytes accelerates hepatocarcinogenesis by driving proliferation and vascular endothelial growth factor-induced angiogenesis", CANCER RESEARCH, vol. 66, no. 3, February 2006 (2006-02-01), pages 1481 - 1490, XP008126824, ISSN: 0008-5472 *
KARAJANNIS M.A. ET AL.: "Activation of FGFR1beta signaling pathway promotes survival, migration and resistance to chemotherapy in acute myeloid leukemia cells", LEUKEMIA, vol. 20, no. 6, June 2006 (2006-06-01), pages 979 - 986, XP007913630, ISSN: 0887-6924 *
KIN M. ET AL.: "Basic fibroblast growth factor regulates proliferation and motility of human hepatoma cells by an autocrine mechanism", JOURNAL OF HEPATOLOGY, vol. 27, no. 4, 1997, pages 677 - 687, XP007913536, ISSN: 0168-8278 *
LIU Z. ET AL.: "Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 51, no. 3, May 2002 (2002-05-01), pages 171 - 177, XP001172419, ISSN: 0340-7004 *
MURATA M. ET AL.: "A comparison of the antitumor effects of interferon-alpha and beta on human hepatocellular carcinoma cell lines", CYTOKINE, vol. 33, no. 3, 7 February 2006 (2006-02-07), pages 121 - 128, XP024907754, ISSN: 1043-4666 *
NOGUCHI R. ET AL.: "Combination of interferon- beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis", CLINICAL CANCER RESEARCH, vol. 9, no. 16, December 2003 (2003-12-01), pages 6038 - 6045, XP008126820, ISSN: 1078-0432 *
OGASAWARA S. ET AL.: "Expressions of basic fibroblast growth factor and its receptors and their relationship to proliferation of human hepatocellular carcinoma cell lines", HEPATOLOGY, vol. 24, no. 1, 1996, pages 198 - 205, XP007913631, ISSN: 0270-9139 *
See also references of EP2165715A4
SIFFROI-FERNANDEZ S. ET AL.: "Acidic fibroblast growth factor (FGF-1) and FGF receptor 1 signaling in human Y79 retinoblastoma", ARCHIVES OF OPHTHALMOLOGY, vol. 123, no. 3, 2005, pages 368 - 376, ISSN: 0003-9950 *
SUZUKI E. ET AL.: "A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients", CLINICAL CANCER RESEARCH, vol. 13, no. 6, 15 March 2007 (2007-03-15), pages 1875 - 1882, XP002508365, ISSN: 1078-0432 *
THE ANTI-ANGIOGENIC ACTIVITY OF RPAI-123 INHIBITS FIBROBLAST GROWTH FACTOR-2 FUNCTIONS, 1 September 2006 (2006-09-01)
TORCIA M. ET AL.: "Interferon-alpha-induced inhibition of B16 melanoma cell proliferation: interference with the bFGF autocrine growth circuit", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 262, no. 3, September 1999 (1999-09-01), pages 838 - 844, XP008126822, ISSN: 0006-291X *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11840558B2 (en) 2008-06-04 2023-12-12 Amgen Inc. Methods of treating non-alcoholic steatohepatitis using FGF21 mutants
US11072640B2 (en) 2008-06-04 2021-07-27 Amgen Inc. Methods of treating non-alcoholic steatohepatitis using FGF21 mutants
US9279013B2 (en) 2008-10-10 2016-03-08 Amgen Inc. FGF-21 mutants comprising polyethylene glycol and uses thereof
WO2010087319A1 (ja) * 2009-01-27 2010-08-05 アステラス製薬株式会社 前立腺癌治療剤として有効な物質のスクリーニング方法
US9493530B2 (en) 2009-05-05 2016-11-15 Amgen Inc. FGF21 mutants comprising a mutation at position 98, 171 and/or 180
US8795985B2 (en) 2009-05-05 2014-08-05 Amgen Inc. FGF 21 polypeptides comprising two or more mutations and uses thereof
US8835385B2 (en) 2009-05-05 2014-09-16 Amgen Inc. FGF21 polypeptides comprising two or more mutations and uses thereof
US8324160B2 (en) 2009-06-17 2012-12-04 Amgen Inc. Chimeric polypeptides and uses thereof
US8372952B2 (en) 2009-12-02 2013-02-12 Amgen Inc. Binding proteins that bind to human FGFR1C, human β-klotho and both human FGFR1C and human β-klotho
US10570205B2 (en) 2009-12-07 2020-02-25 Amgen, Inc. Human antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereof
US9493577B2 (en) 2009-12-07 2016-11-15 Amgen Inc. Human antigen binding proteins that bind β-klotho, FGF receptors and complexes thereof
US9284378B2 (en) 2009-12-07 2016-03-15 Shaw-Fen Sylvia Hu Human antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereof
JP2012025694A (ja) * 2010-07-23 2012-02-09 Asahi Kasei Kuraray Medical Co Ltd 癌治療剤
JP2014523866A (ja) * 2011-05-16 2014-09-18 ジェネンテック， インコーポレイテッド Ｆｇｆｒ１アゴニスト及び使用方法
WO2013129549A1 (ja) * 2012-02-29 2013-09-06 東レ株式会社 体腔液貯留抑制剤
JP2015530976A (ja) * 2012-07-24 2015-10-29 ザ トラスティーズ オブ コロンビア ユニバーシティ イ 融合タンパク質およびその方法
US11920138B2 (en) 2012-07-24 2024-03-05 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
WO2014138364A2 (en) 2013-03-06 2014-09-12 Genentech, Inc. Methods of treating and preventing cancer drug resistance
WO2015191986A1 (en) 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance

Also Published As

Publication number Publication date
JPWO2008149521A1 (ja) 2010-08-19
EP2165715A4 (en) 2010-08-04
EP2165715B1 (en) 2013-12-18
US20110129524A1 (en) 2011-06-02
JP5563818B2 (ja) 2014-07-30
EP2165715A1 (en) 2010-03-24
CA2689242C (en) 2015-07-07
CA2689242A1 (en) 2008-12-11
US8481497B2 (en) 2013-07-09

Similar Documents

Publication Publication Date Title
WO2008149521A1 (ja) 癌治療剤及び癌の治療方法
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
HK1120441A1 (en) Drugs for treatment of ovarian cancer
AU2006226733A8 (en) Antibodies against CD38 for treatment of multiple myeloma
UA99633C2 (ru) Антитело, специфически связывающееся с человеческим белком ron
WO2010066803A3 (en) Human antibodies against human tissue factor
WO2004103274A3 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
AU2006226897B2 (en) Combinations for the treatment of cancer comprising anti-EGFR antibody and VEGFR inhibitors
WO2009007749A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
WO2003097052A3 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
WO2008132234A3 (en) Rna antagonist compounds for the modulation of beta-catenin
WO2007127010A3 (en) Diarylthiohydantoin compounds
WO2010004204A3 (fr) Antagonistes specifiques du recepteur fgf-r4
WO2009020933A3 (en) Therapeutic use of anti-tweak receptor antibodies
WO2008037257A3 (en) Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
MX2009006401A (es) Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer.
WO2007150077A8 (en) Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2008138904A3 (en) Rna antagonist compounds for the modulation of her3
WO2009063970A1 (ja) 抗gpr49抗体を用いる癌の診断および治療
WO2007146957A3 (en) Ror1 as a therapeutic target for lung cancer
WO2003101444A8 (en) Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
IL180256A0 (en) Pyrido-pyrido pyrimidine derivatives, preparation thereof, therapeutic use thereof for treating cancer
WO2010077589A3 (en) Stat3 inhibitors and therapeutic methods using the same
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
TNSN07440A1 (en) Derivatives of pyrido [2,3 -d] pyrimidine, the preparation thereof, and the therapeutic application of the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08763946

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2009517707

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2689242

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008763946

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12601811

Country of ref document: US